Alembic Group, founded in 1907, is a diversified conglomerate with businesses in pharmaceuticals, real estate, and chemicals. Its flagship company, Alembic Pharmaceuticals, is a leading player in the industry, while Alembic Real Estate and Alembic Chemicals contribute to its overall revenue and growth.
Table of Contents
Alembic Group’s Company Overview and History
Alembic Group, established in 1907, is one of India’s oldest industrial conglomerates. With a strong presence in pharmaceuticals, real estate, and chemicals, the group has grown significantly, contributing to India’s economic and industrial landscape over the decades.
The group’s flagship entity, Alembic Pharmaceuticals, has a multi-billion-dollar valuation and is a key player in the global pharmaceutical market. Owned primarily by the Patel family, it ranks among India’s top pharmaceutical companies, with a growing international footprint and a strong research-driven approach.
Alembic Group Financials and Shareholder Returns
Alembic Group reported a revenue of ₹4,001.10 crore and a net profit of ₹349.60 crore in FY 2024. With a 0.36% dividend yield, its stock delivered strong returns—63.20% in one year, 77.20% in three years, and 78.40% in five years.
| Metric | Value |
| Revenue (FY 2024) | ₹6,256.90 crore |
| Net Profit (FY 2024) | ₹615.8 crore |
| Dividend Yield | 1.31% |
| 1-Year Return | -9.90% |
| 3-Year Return | 5.03% |
| 5-Year Return | 9.14% |
How Alembic Group Started and the Growth of Its First Business
Alembic Group began its journey in 1907 with Alembic Pharmaceuticals, founded by Prof. T.K. Gajjar, Rajmitra Lalbhai, and B.D. Amin. It started as a small-scale pharmaceutical company producing tinctures and alcohol-based formulations in an era when India’s pharmaceutical sector was still in its infancy.
During that period, the industry relied heavily on imports, and Alembic played a key role in developing indigenous pharmaceutical manufacturing. Over the decades, it expanded into formulations and APIs. Today, Alembic Pharmaceuticals is led by Pranav Amin and Shaunak Amin, who continue driving its growth and global expansion.
Below is a chart showcasing the current revenue of Alembic Pharmaceuticals Ltd, the flagship company of Alembic Group:
How Did Alembic Group Expand into Subsequent Business Sectors?
Alembic Group strategically expanded beyond pharmaceuticals, diversifying into new sectors to strengthen its business portfolio. Over the years, it ventured into real estate and chemicals, leveraging its expertise to establish a strong presence in multiple industries.
- 1907: Established as Alembic Chemical Works Company Ltd. by Prof. T.K. Gajjar, Prof. A.S. Kotibhasker, and B.D. Amin, focusing on tinctures, alcohol, vitamins, and penicillin production.
- 1943: Ventured into glass bottle manufacturing due to supply chain disruptions from Europe during World War II.
- 1944: Incorporated Alembic Glass Industries Ltd., later renamed Shreno Ltd. in 2005 to differentiate from the pharmaceutical business.
- 1958: Launched YERA, India’s largest glassware brand, further expanding the group’s industrial footprint.
- 2009: Founded Alchemy Real Estate, the real estate arm of Alembic Group, developing residential, commercial, and industrial projects in Gujarat.
- 2010: Demerged its pharmaceutical business, forming Alembic Pharmaceuticals Ltd., now India’s oldest pharmaceutical company.
- 2014: Alchemy Real Estate expanded beyond Gujarat, launching its first project in Bengaluru, Karnataka.
Alembic Group Revenue Split: How Alembic Group Earns Across Different Sectors
Alembic Piramal Group operates across various companies, each contributing uniquely to its revenue. Here’s an overview:
- Alembic Pharmaceuticals Ltd: Alembic Pharmaceuticals Ltd is a leading Indian pharmaceutical company specializing in active pharmaceutical ingredients (APIs), formulations, and generics. With ₹6,256.90 crore revenue in FY 2024, it focuses on innovation, research, and manufacturing high-quality medicines across multiple therapeutic areas.
- Alembic Ltd: Alembic Ltd, the parent company of Alembic Group, operates in pharmaceuticals, chemicals, and real estate. Established in 1907, it has diversified its portfolio over decades, contributing significantly to India’s industrial growth. It reported ₹212.30 crore revenue in FY 2024, reflecting its strong business presence.
- Paushak Ltd: Paushak Ltd is a specialty chemical company under Alembic Group, engaged in producing phosgene-based intermediates for pharmaceuticals, agrochemicals, and performance chemicals. With ₹226.80 crore revenue in FY 2024, it plays a crucial role in niche chemical markets, ensuring high safety standards and global regulatory compliance.
Challenges Faced by Alembic Group Across Its Businesses
The main challenges faced by Alembic Group across its businesses include regulatory hurdles, market competition, supply chain disruptions, and evolving industry dynamics. These factors impact growth, profitability, and innovation, requiring strategic planning, technological advancements, and adaptability to sustain long-term success.
- Regulatory Hurdles: Strict compliance requirements in pharmaceuticals and chemicals pose challenges for Alembic Group. Changing global and domestic regulations demand continuous investment in quality control, research, and legal expertise to meet standards while ensuring seamless product approvals and market entry.
- Market Competition: Alembic faces intense competition from domestic and international players across its business segments. Price wars, innovation races, and market consolidation make it crucial to differentiate products, strengthen brand positioning, and enhance research capabilities for sustained growth.
- Supply Chain Disruptions: Fluctuations in raw material availability, logistics delays, and geopolitical factors impact operations. The group must optimize sourcing strategies, maintain inventory efficiency, and invest in alternative supply channels to mitigate risks and ensure smooth business continuity.
- Evolving Industry Dynamics: Rapid technological advancements, changing consumer preferences, and healthcare shifts impact business sustainability. Alembic Group must embrace digital transformation, invest in R&D, and explore emerging trends to stay ahead in the pharmaceuticals, chemicals, and real estate industries.
How does Alembic Group’s future look in Terms of Growth and Strategy?
The main focus of Alembic Group’s future growth and strategy revolves around innovation, global expansion, sustainability, and digital transformation. The company aims to strengthen its market position by investing in R&D, diversifying its portfolio, and leveraging emerging technologies to drive long-term success.
- Innovation and R&D Investment: Alembic Group is increasing its focus on research and development to introduce advanced formulations, specialty chemicals, and high-value products. Expanding its R&D capabilities will help it maintain a competitive edge and meet evolving industry demands.
- Global Expansion: The company is actively enhancing its presence in international markets, particularly in the U.S., Europe, and emerging economies. Strategic acquisitions, regulatory approvals, and partnerships will drive geographical diversification and revenue growth.
- Sustainability and Green Initiatives: Alembic Group is adopting eco-friendly manufacturing practices, reducing its carbon footprint, and ensuring compliance with environmental regulations. Sustainability-driven strategies will help in long-term cost efficiency and align with global ESG (Environmental, Social, and Governance) standards.
- Digital Transformation and Automation: The company is integrating advanced digital solutions, AI-driven analytics, and automation across its operations. These initiatives aim to improve efficiency, enhance decision-making, and optimize production and supply chain management for future growth.
Alembic Group’s Expansion Plans and Growth Strategy
Alembic Group is actively expanding its business through strategic investments in research, innovation, and global market penetration. The company aims to strengthen its pharmaceutical, specialty chemicals, and real estate segments by enhancing production capabilities, acquiring regulatory approvals, and launching high-value products in key international markets.
To drive long-term growth, Alembic Group is focusing on sustainability, digital transformation, and operational efficiency. By integrating advanced technologies, optimizing supply chains, and adopting eco-friendly practices, the company seeks to enhance profitability, improve market competitiveness, and establish itself as a leader across diverse industries.
How to invest in Alembic Group Stock?
If you are looking to invest in Alembic Group stock, you can easily do so through Alice Blue, where purchasing stocks is absolutely free with zero brokerage on equity delivery trades.
Step 1: Open a Demat & Trading Account
- Visit Alice Blue’s website
- Click on “Open Demat Account” and complete the registration.
- Upload your PAN, Aadhaar, and bank details for verification.
Step 2: Add Funds to Your Trading Account
- Log in to Alice Blue and go to the Funds section.
- Add money via UPI, Net Banking, or NEFT/RTGS for smooth transactions.
Step 3: Search & Analyze Alembic Group Stock
- Use the search bar to find Alembic Group shares.
- Check the market price, charts, and company details before investing.
Step 4: Place Your Buy Order
- Click Buy and choose Market Order (instant purchase) or Limit Order (buy at your set price).
- Enter the quantity and confirm your order.
Alembic Group Company Overview and Revenue Split – Quick Summary
- Founded in 1907, Alembic Group is a diversified Indian conglomerate engaged in pharmaceuticals, specialty chemicals, glass, and real estate, with a legacy of innovation and industry leadership.
- Alembic Group posted ₹4,001.10 crore revenue and ₹349.60 crore net profit in FY 2024. With a 0.36% dividend yield, its stock returned 63.20% in one year, 77.20% in three years, and 78.40% in five years.
- Alembic Group began as Alembic Chemical Works in 1907, producing tinctures and penicillin. It expanded into pharmaceuticals, becoming a key player in India’s pharmaceutical industry, focusing on research-driven growth.
- Alembic Group entered glass manufacturing in 1943, specialty chemicals in 1972, and real estate in 2009, and continues expanding strategically across industries through acquisitions, innovation, and market-driven diversification.
- Alembic Pharmaceuticals contributes ₹6,256.90 crore, Paushak Ltd ₹226.80 crore, and Alembic Ltd ₹212.30 crore. Pharmaceuticals remain the largest revenue driver, followed by chemicals and real estate.
- Alembic Group faces challenges of regulatory changes, pricing pressure, rising competition, and R&D investment challenges that impact Alembic’s growth. The company focuses on innovation, operational efficiency, and global expansion to navigate these obstacles.
- Alembic Group aims to expand pharmaceutical exports, strengthen specialty chemicals, grow real estate ventures, and enhance R&D capabilities, ensuring sustainable long-term growth and market leadership.
- Alembic Group focuses on global pharmaceutical expansion, increasing domestic manufacturing, diversifying specialty chemicals, and leveraging technological advancements to drive innovation and market competitiveness.
- Open a free demat account with Alice Blue in 15 minutes today! Invest in Stocks, Mutual Funds, Bonds & IPOs for Free. Also, trade at just ₹ 20/order brokerage on every order.
Alembic Group Stock And Its Revenue Across Business Segments – FAQs
Alembic Group generates revenue from its key businesses with Alembic Pharmaceuticals Ltd contributing ₹6,256.90 crore, Alembic Ltd ₹212.30 crore, and Paushak Ltd ₹226.80 crore. The pharmaceutical segment remains the largest revenue driver, followed by specialty chemicals and diversified industrial operations.
Alembic Group operates in pharmaceuticals, specialty chemicals, real estate, and glass manufacturing. It focuses on producing active pharmaceutical ingredients, formulations, and specialty chemicals while also developing residential and commercial real estate projects, contributing significantly to India’s industrial and healthcare sectors.
Alembic Group is owned and managed by the Amin family, with Chirayu Amin serving as Chairman. The group, founded in 1907, has grown into a leading conglomerate, maintaining strong leadership in pharmaceuticals, chemicals, and diversified industrial ventures across multiple business sectors.
The key businesses under Alembic Group include Alembic Pharmaceuticals Ltd, specializing in pharmaceuticals, Paushak Ltd, focusing on specialty chemicals, Alembic Ltd, managing industrial and real estate ventures, and Shreno Ltd, handling glass manufacturing and other diversified operations to support overall growth.
Alembic Group generates annual revenue of approximately ₹6,696 crores, with major contributions from its pharmaceutical, speciality chemicals, and industrial segments. The group continues to expand its businesses, leveraging innovation and global expansion to drive sustained financial growth.
The pharmaceutical segment contributes the most to Alembic Group’s revenue, with Alembic Pharmaceuticals Ltd generating ₹6,256.90 crore annually. This accounts for the majority of the group’s earnings, followed by specialty chemicals through Paushak Ltd and industrial ventures under Alembic Ltd.
Alembic Pharmaceuticals Ltd, the main stock of Alembic Group, has shown mixed performance over the years. It delivered a -9.90% return in the past year, a 5.03% gain over three years, and a moderate 9.14% return over five years.
Alembic Group has issued bonus shares in the past as part of its shareholder reward strategy. Bonus issuance depends on financial performance and board decisions. Investors should check company announcements for updates on potential future bonus share distributions.
Alembic Pharmaceuticals Ltd, the key company of Alembic Group, has major shareholders including promoters holding 69.60%, foreign institutional investors (FII) at 4.20%, domestic institutional investors (DII) at 16.10%, and the public owning 10.20% as of December 2024.
Alembic Pharmaceuticals, a key company of Alembic Group, recently acquired the remaining 40% stake in Aleor Dermaceuticals from Orbicular Pharmaceutical Technologies. This acquisition strengthens its dermatology segment, enhancing its manufacturing capabilities in Gujarat and expanding its presence in the US market.
Disclaimer: The above article is written for educational purposes and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
